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Evaluation of bronchodilator response 
in patients with airway obstruction 
S. A. QUADRELLI, A. J. RONCORONI AND G. C. MONTIEL 
Instituto de Investigaciones Mkdicas Alfred0 Lanari, Facultad de Medicina, Universidad de Buenos Aiues, 
Argentina 
The aim of this study was to define the most useful index of expressing bronchodilator response and to distinguish 
between asthma and COPD. 
A prospective study was carried out of bronchodilator response in 142 asthmatics and 58 COPD patients in a 
university hospital. 
Reversibility was expressed as: 1. absolute change (dabs); 2. % of initial (A %init); 3. % of predicted (A %pred) 
and 4. % of maximum possible response (A %max). Dependence on forced expirations volume in 1 set (FEV,) as % 
of predicted and sensitivity and specificity for diagnosis of asthma were established. 
A relationship between dabs and initial FEVl was not found in asthma (dabs vs. % initial FEV1. r= 0.07) or 
COPD (I = 0.02). A%pred did not show a correlation in asthma (v=O.lO) or COPD (u= 0.06). A?/oinit was 
dependent on the baseline value in asthma (r=0.38 , Pi 0,001 ) but not in COPD (r=O.lS , P=n.s.). dmax was 
dependent in both. The combination of best sensitivity and specificity to separate asthma and COPD was obtaiced 
with dabs (70.4 or 70.6%). The worst specificity for asthma diagnosis was obtained with A% init (50%). The best 
likelihood ratios were obtained with dabs and A%pred and the worst likelihood ratio with A%init 
A%init is not recommended as an index for differential diagnosis between asthma and COPD; 2) A%init 
overscores bronchodilator response in patients with low FEV,. The independence of each bronchodilator response 
index should be verified in clinical trials for each selected sample. 
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Introduction 
The measurement of spirometric data before and after 
inhaling a bronchodilator is a commonly ordered pulmon- 
ary function test in clinical and research settings. Despite its 
well-known limitations, it is one of the most useful criteria 
for asthma diagnosis. Additionally, most clinical trials 
define ‘reversible’ vs. ‘non-reversible’ airway obstruction 
depending on bronchodilator response, which theoretically 
determines homogeneous study samples. However, there 
are no uniformly accepted criteria for defining a ‘significant’ 
response (1,2). Questions to answer are: 1. which spiro- 
metric indices should be considered to evaluate response 
[forced expiratory volume in 1 set (FEV,), forced vital 
capacity (FVC), forced expiratory flow between 2.5 and 
75% of FVC (FEFzz-75) and FEVl/FVC]?; 2. which is the 
best way to express change after inhaling a bronchodilator 
(absolute change, percentage of initial FEVl , percentage of 
predicted FEVl, percentage of maximal possible response)? 
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and 3. what amount of change should be considered a 
positive response? 
Although a percentage of the initial FEVl value is not 
either a part of the definition of bronchodilator response 
for international societies nor universally accepted, it is a 
very common means of expression. An increase in FEVI 
215% was the most popular definition of a positive 
bronchodilator response found in a review of the asthma 
and chronic obstructive pulmonory disease (COPD) litera- 
ture and some medical settings (3). However, this criterion 
has recently been challenged due to an inadequate ability to 
separate diagnostically asthma and COPD patients (4) and 
mainly because of the generation of a much greater 
proportion of responsive patients (probably false) among 
patients with very low initial FEVl (5-7). On the other 
hand, expressing change as an absolute value (for instance, 
200 ml) may theoretically require values impossible to 
achieve for patients with very low FEV1, thus creating a 
falsely high proportion of non-responsive tests. Choosing 
one or the other criterion may result in a different 
classification of a relevant number of patients (5). 
These difficulties have provoked increasing interest in 
exploring other ways to express bronchodilator response 
(8,9). The characteristics of an ideal index should be 
maximal independence of the pre-bronchodilator FEVl 
value, greatest power to discriminate asthma and COPD 
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and the reproducibility of bronchodilator response. We 
have examined the different ways of expressing bronchodi- 
lator response in patients with previously known disease 
(asthma and COPD) in order to define their dependence on 
initial FEVr and their efficacy to separate patients with 
asthma from patients with COPD. 
Material and Methods 
Two hundred patients with airway obstruction were studied 
during a routine visit in our chest clinic (142 asthmatics, 58 
COPD). They were included in the study if they had a 
previously diagnosed airway obstructive disease and a 
present baseline spirometry with a FEVi/FVC relationship 
1.64 SEE below the predicted value or lower. All COPD 
patients showed FEV, values lower than 10% of predicted 
value. To test the power of each index to discriminate 
between COPD and asthma patients, a comparison was 
performed studying the subgroup of asthmatics with FEVi 
lower than 55% of predicted value (n = 61) in order to 
match COPD and asthma patients for baseline lung 
function. Patients with other chronic respiratory diseases 
(occupational lung disorder, bronchiectasis, interstitial lung 
disease, tuberculosis and cancer), previous thoracic surgery, 
heart failure or any other condition able to interfere with an 
adequate expiratory manoeuvre or a correct classification 
of asthma or COPD were excluded. A standardized history 
of respiratory symptoms was obtained. Patients were 
classified as asthmatics when they reported attacks of 
breathlessness and wheeze according ATS criteria and were 
non-smokers. All the asthmatic patients had been followed 
at our hospital for some years. All of them had at least two 
of the following criteria: 1. history of symptoms since 
childhood or adolescence; 2. symptomatic-free periods of 
longer than 3 months; 3. spontaneous variations of FEVi 
during the year of over 20% of baseline value; 4. a 
histamine challenge test with a PC& under 8 mg ml-‘. 
Patients were classified as COPD when they were heavy 
current or ex-smokers with no history of asthma, reporting 
chronic cough with sputum. To avoid misclassification, 
patients with history suggesting asthma but who were 
smokers and patients with history suggesting COPD but 
who were not smokers were not included, even though a 
small group of asthmatics can be smokers and a few COPD 
patients are not ex- or current smokers. Patients not clearly 
classified as one or the other group were not included. 
Patients under current treatment with systemic steroids were 
excluded. All patients with asthma were receiving inhaled 
steroids and bronchodilators following international step- 
wise guidelines. COPD patients were not receiving inhaled 
steroids but only regular treatment with inhaled broncho- 
dilators and theophylline during symptomatic periods. 
All spirometric tests were performed in the seated 
position by the same two technicians according to 
standardized guidelines. Calibration was checked every 
day. Patients were requested to abstain from inhaled 
steroids, theophylline and bronchodilators for at least 12 
h before the study. FEVi and FVC were assessed at least 
three times with a dry wedge bellows spirometer (Vitalo- 
graph, London, U.K.). The data from the flow-volume 
curve with the highest sum of FVC and FEVr were used for 
calculations. The FEVr was measured before and 20 min 
after inhalation of 200 ug salbutamol from a metered dose 
inhaler (Glaxo, Argentina). 
The bronchodilator (Bd) response of each patient was 
expressed in four different ways: 1. absolute change (dabs): 
FEVi post-FEV, pre-Bd; 2. percentage of initial FEVi 
(A %init): (FEVi post-Bd- FEVi pre-Bd/FEVi pre- 
Bd) x 100; 3. percentage of predicted FEVi (A%pred): 
(FEVi post-Bd-FEVi pre-Bd/predicted FEVr) x 100; and 
4. percentage of maximal possible response (d%max): 
[(FEVr post-Bd - FEVr pre-Bd)/(predicted FEVi - FEVi 
pre-Bd)] x 100. All negative changes were classed as zero. 
In order to investigate the dependence of each index on 
baseline FEV,, linear regression analysis of the broncho- 
dilator response was applied, taking the Pearson correlation 
coefficient as a measure of the extent of the relationship. 
The two-tailed t-test for unpaired samples was applied to 
compare group means. 
The sensitivity and specificity of a bronchodilator 
response to salbutamol in separating patients with asthma 
and COPD were calculated applying most commonly 
published values (dabs 200 ml, Ainit 15%) or values 
derived from confidence intervals previously obtained in 
studies with placebo in our pulmonary function laboratory 
(A % pred 9%, A %max 50%) (10). The predictive value for 
a positive test [true positives/(true positives + false posi- 
tives)] and the predictive value for a negative test [true 
negatives/(true negatives + false negatives)] were calculated 
on the basis of an arbitrarily chosen clinical pre-test 
probability of asthma of 30 and 70%. The likelihood ratio 
(sensitivity/l -specificity), which reflects the ability of a test 
to discriminate between subjects with asthma or COPD was 
also calculated for each index (11). For this analysis, two 
different samples were studied: 1. the whole sample of 
asthmatics vs. COPD and 2. the sample of asthmatics with 
FEVt lower than 55% of predicted value vs. COPD. 
Results 
Of the 200 patients, 142 were classed as asthmatic (mean 
age 55.4* 19.0 years, 68 women) and 58 as COPD (mean 
age 67.3 + 7.0 years, 12 women). Baseline FEVi in asthma 
patients was 1.57 kO.76 1 (59.4f 19.1 % of predicted) and 
in patients with COPD 1.01 kO.34 1 (39.7 * 14.7% of 
predicted). CVF was 2.59 ho.87 1 (80.6 +20.2% of pre- 
dicted) in asthmatics and 1.23 + 0.55 1 (60.2 i 13.7% of 
predicted) in COPD. Of the COPD patients 23% were 
current smokers and 77% ex-smokers (68.3 i 36.5 pack 
years). Sixty-one asthmatic patients showed an FEVi lower 
than 55% of predicted (mean FEVi 41.9 + 8.7%). 
RELATIONSHIP BETWEEN BASELINE FEVl 
AND BRONCHODILATOR RESPONSE 
There was no relationship between dabs and pre-Bd FEV, 
either in asthmatics or in COPD. Changes expressed as 
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TABLE 1. Correlation coefficient (r)for asthma and COPD vs. absolute FEVr and FEVr % predicted 
vs. baseline FEVr (absolute value) vs. baseline FEVr (% of predicted) 
Asthma COPD Asthma COPD 
P P P P 
AFEVr absolute 0.14 n.s. 0.12 n.s. 0.07 ns. 0.02 n.s. 
A% FEVr initial 0.26 <0.005 0.18 n.s. 0.38 <O.OOl 0.18 n.s. 
A% FEVr predicted 0.06 ll.S. 0.06 n.s. 0.10 n.s. 0.06 ns. 
A% maximal possible 0.07 n.s. 0.42 <o-o01 0.22 <O.OOl 0.27 <O.Ol 
Asthma, rz = 142; COPD, n = 58. 
n.s., not significant; bold type indicates significant difference. 
A%red, did not show correlation with pre-Bd FEV, in 
asthmatics or in COPD (Table 1). 
On the other hand, the bronchodilating response 
expressed as a percentage of the initial value was dependent 
on pre-Bd FEVr in asthmatics, although not in COPD. 
Bronchodilator responsiveness expressed as a percentage of 
the maximal possible response tends to infinity when pre-Bd 
FEVl is equal or higher than predicted, therefore it cannot 
be calculated in these situations. The correlation coefficient 
was calculated excluding such cases, although the scattering 
of A%max was very important. A%max was dependent on 
pre-Bd FEVr as % predicted in asthmatics and COPD 
(Table 1). When the sample was considered as a whole 
(asthma+COPD) (n=200) dabs (r=O.O3, P=n.s.) (Fig. 1) 
and A %pred (r = 0.02, P = n.s.) (Fig. 2) were still indepen- 
dent of pre-Bd FEVr. However A% init (v = 0.37, P< 0,001) 
(Fig. 3) and A%max (Y= 0.22, P-cO.005) were dependent 
on the pre-Bd FEVr value. 
BRONCHODILATOR RESPONSE IN 
PATIENTS WITH ASTHMA AND COPD 
Bronchodilator response was significantly different between 
asthmatics and COPD when expressed as dabs (asthma 
0.31 ~tO.22 IJS. COPD 0.16f0.14; 1 P<O.OOl) or A% pred 
(asthma 12.0 LII 7.9 IX 6.29 rt 5.1%; P<O,OOl). Change 
expressed as A%init or A%max was not different between 
both groups of patients (Table 2, Fig. 4). However, if only 
patients with reduced FEVr (lower than 55% of predicted) 
were considered, all indices reached statistical significance 
in separating asthma and COPD (Table 2, Fig. 4). 
Bronchodilator response did not show a sensitivity 
higher than 85% to establish asthma diagnosis for any 
index. The lowest specificity was obtained with A% init 
(50.0%) (Table 3). When predictive values for a positive 
and negative test were calculated on the basis of an 
arbitrarily chosen clinical pre-test probability of asthma of 
30 and 70%, the best predictive values for a positive test 
were obtained with dabs (50.5 and 84.8%) and A% pred 
(49.2 and 84.1%), while the lowest predictive value for a 
positive test (39.4 and 78.0%) was obtained with A%init. 
Even with a high predictive value for a positive test, 
Bronchodilator response as % of initial FEVl 
FIG 1. Relation between pre-Bd FEVr as a percentage of 
predicted and A%init in the whole population 
(asthma + COPD) (n = 200). There was strong dependence 
on the degree of baseline airflow obstruction (v=O.33, 
P= <O.OOl; y= -0.5203x+62.338). 
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FIG. 2. Relation between pre-Bd FEVr as a percentage of 
predicted value and A%pred in the whole population 
(asthma + COPD) (n = 200). Dependence on the degree of 
baseline airflow obstruction was not found in the 
complete sample (r = 0.02 , P = n.s.; y = 0.057 1 x + 54.065). 
A %max had very low values of sensitivity (19.0%) and a 
low predictive value for a negative test (Tables 3 and 4). 
The most powerful indices for discriminating between 
asthma and COPD were dabs and A%pred as they showed 
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FIG. 3. Relationship between pre-Bd FEVl as a 
percentage of predicted value and dabs in the whole 
population (asthma + COPD). Dependence on the degree 
of baseline airflow obstruction was not found (r = 0.03, 
P=n.s.; y=2.9212~+ 53.899). 
the highest likelihood ratios (2.23 and 2.03); much higher 
than values for A%init (1.28). If only those asthmatics with 
lower FEVl values were considered (to match the patients 
for baseline lung function), the results were not notably 
different. 
A subgroup of 8(5.6%) patients were classed as 
bronchodilator-responsive when applying A%pred but as 
(a) 
40 
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TABLE 2. Response to bronchodilator: comparison between 
patients with asthma and COPD 
Patients with FEVl lower than 55% 
of predicted 
Asthma COPD P 
AFEVl abs (1) 0*32&0.20 0.16$0.14 <O*OOl 
A% FEVl init (%) 26.5+ 14.6 16.9+ 14.9 co.05 
A% FEVl pred (%) 13.217.9 6.29Jr5.1 <O~OOl 
A% m6x (%) 23.55 15.3 2.9553.23 <O.OOl 
non-responsive when applying A%init (A% pred > 9%, 
A%init < 15%). When these patients were compared with 
the opposite situation (non-responsive on applying A%pred 
but responsive on applying A% init: n= 12, i.e. 8.4% of 
patients), they showed a higher pre-Bd FEVl (78.6f 14.7 
~~37.1 f 8.1 % predicted, P= <O.OOl). No COPD patient 
was classed as responsive by only A%pred > 9%, because 
all such patients showed a corresponding A% init of 
> 15%. However, 10 patients (17.2%) who were classified 
as non-responsive according to A%pred < 9% showed A% 
init>15%. 
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FIG. 4. Distribution of bronchodilator response in asthma (@and COPD expressed by different indices (patients with 
FEVl below 55% of predicted). Bronchodilator response as: (a) absolute change; (b) % of possible maximum; (c) % of 
baseline FEV1; and (d) % predicted. 
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TABLE 3. Response to bronchodilator: sensitivity and specificity of different indices in patients 
with FEVi <55% (asthma: n=61) 
Index Cut-off level True responsive Sensitivity Specificity 
dabs 200 ml 43 704% 70.6% 
A %init 15% 52 85.2% 50.0% 
dabs + A % init 42 68.8% 70.6% 
A %pred 9% 41 67.2% 706% 
A% max 50% 4 6.5% 98.2% 
Bold type indicates significant difference. 
TABLE 4. Response to bronchodilator: predictive values for a positive and negative test for 
patients with FEVi lower than 55% (asthma: n=61) 
Pre-test probability of asthma 30% Pre-test probability of asthma 70% 
PV for a positive PV for a negative PV for a positive PV for a negative 
Index test (%) test (%) test (%) test (%) 
A%abs 50.5 x4.7 848 50.6 
A%init 39.4 82.9 78.0 47.3 
dabs + A% init 48.1 81.9 83.5 45.5 
A %pred 49.2 83.1 84.1 47.5 
A% mix 75.5 72.3 94.5 324 
The clinical usefulness of each index is highly dependent on clinical pre-test probability of 
asthma. A%init shows the worst results of predictive values for a positive or negative test in most 
circumstances. In patients with high clinical pre-test, the presence of a positive reponse expressed 
as A%max may be a very specific diagnostic index. Bold type indicates significant difference. 
Discussion 
This study demonstrates that expressing bronchodilator 
response in one of the most popular ways (increase in FEVi 
as a percentage of baseline FEVi) has important disadvan- 
tages: it is strongly dependent on the pre-bronchodilator 
FEVr, does not reveal significant differences between 
asthma and COPD patients and shows the weakest power 
to discriminate between these two conditions. 
In order to define reversibility to bronchodilator, three 
factors should be considered: 1. which will be the applied 
indices? (FEVi, FVC, FEFzTm7s?); 2. which will be the 
chosen way of expressing this response? and 3. which will be 
the cut-off limits to define a positive response? 
Firstly, FEVi was better than other commonly used tests 
for evaluating bronchodilating drugs (5,12). Secondly, the 
cut-off limits of a positive response may be defined from 
studies using patient samples to determine confidence 
intervals for spontaneous variability (13) or placebo 
response (10,14), or may be calculated from the response 
to bronchodilator in normal subjects (1.5). Taking into 
account that the distribution of bronchodilator response in 
any of those popu!ations is continuous and unimodal, any 
definition of the ‘cut-off level for a positive response will be 
arbitrary. The chosen values for this study were derived 
from confidence intervais for response to placebo obtained 
at our pulmonary function laboratory (lo), which are 
similar to currently published values (1,16). 
Finally, if the two most commonly used indices for 
expressing response (dabs and do&nit) are analysed, it 
seems obvious that a change of 200 ml may be a small 
variation in a baseline FEVi of 2.5 1 (< lo%), while it may 
be almost impossible to achieve for a very low baseline 
FEVi, e.g. 0.4 1 (50%). At the same time, a change of 15% 
in initial value may be a very low value in the second 
example (60 ml), with equivocal clinical significance and 
even the possibility of under-resolution of the spirometry 
equipment. The number of patients classed differently 
according to the different criteria is not small (12% of 
asthmatics in a study population) (5) and is important in 
defining which index is more accurate. 
An index with a greater independence of baseline FEVi 
increases the comparability between different subjects and 
also between tests with different baseline FEVi in the same 
subject (5,17). According to our results in patients with 
asthma, only dabs and A%pred were independent of pre- 
Bd FEV,, while in COPD patients only A%max showed a 
strong dependence on the baseline FEVi value. These 
results in COPD patients contrast with data obtained by 
Dompeling et al. (17), where A%init was very dependent on 
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TABLE 5. Comparison of relationships between different 
indices and baseline FEV, in published studies 
Index Dompelir$ Brand*** Weir§** Actual+ 
(17) (8) (9) 
dabs 
A %init 
A%pred 
A %max 
0.09* 0.14’ 0.17 0.07* 
0.18** 0.02** 
0.45” 0.40” 0.19 0.38” 
0.47** 0.18** 
0.23” 0.16+ 0.11 0.10* 
0.35** 0.06** 
0.20* 0.30 0.22* 
0.20** 0.27*” 
* Asthma; ** COPD; ***Mixed; ‘Correlation coefficient; 
D Spearman coefficient. 
Results are different in different studies. However, despite 
the different population compositions (asthma, COPD or 
mixed) and different statistical analyses (correlation coeffi- 
cient or Spearman coefficient) the dependence of A%init on 
pre-Bd FEVi is consistently observed. Nevertheless, the 
heterogeneity of results shows the influence of population 
characteristics on diagnosis and severity of airway disease. 
pre-Bd FEVi. Differences in patient selection may explain 
this disagreement. Dompeling’s patients showed a much 
lower degree of bronchial obstruction than ours (baseline 
FEVi 77 + 18% vs. 39.7 + 14.7% predicted) and a higher 
response to bronchodilator (dabs 0.26& 0.14 1 vs. 
0.16 + 0.14 1). The higher homogeneity of our sample (and 
perhaps the smaller number, n = 58 vs. 111) may be the 
reason for the absence of the dependence showed by 
Dompeling et al. (17). Despite this difference, our data and 
results from other authors (9, 17) strongly suggest that the 
most popular index (do/&nit) is highly dependent on the 
baseline value in asthma (8) or in a non-selected patient 
population (9) (v for our population as a whole =0.33, 
P= <O.OOl). 
This fact is remarkably relevant when defining bronch- 
odilator response in clinical trials or in patients in different 
clinical situations. If an inclusion criterion is a pre- 
determined level of bronchodilator response expressed as 
A%init (which is very common) (1819) this will select 
patients with a more severe pre-bronchodilator airway 
obstruction. On the other hand, if the sample is composed 
of more severely affected patients, the response to 
bronchodilator as a percentage of initial value will be 
magnified due only to the chosen criterion. Similarly, the 
response to any bronchodilator in a patient who has 
experienced great change in his or her baseline FEVi may 
be falsely interpreted as different. This potential error 
would be avoided if response were expressed as dabs. 
Finally, in light of the strong dependence of A%init, the 
prognostic significance of bronchodilator responsiveness in 
COPD patients should be reconsidered. A worse prognosis 
for patients with higher reversibility (expressed as A%init) 
has been reported (20,21). However, is this really the 
influence of reversibility or solely due to the selection of 
more severe patients who show a greater response when ex- 
pressed as A%init? (22). Interestingly, when Postma et al. 
(23) assessed response to bronchodilator using A% (pred - 
initial), a higher reversibility was a favourable prognostic 
criterion. 
It is remarkable that several different studies which have 
analysed the dependence of bronchodilator response on 
pre-bronchodilator values, while in accord over the strong 
dependence of A%init, show very different results regarding 
other methods of expressing reversibility (Table 5). 
Obviously, the composition of the sample is critical in 
determining such relationships. This is very important in 
designing clinical trials and the chosen method of expres- 
sing bronchodilator response should be assessed in that 
particular sample to exclude dependence on baseline FEVi. 
Even when advantages of dabs and A%pred in separat- 
ing positive and negative responses are clear, the prognostic 
significance of these indices in evaluating the long-term 
outcome has not been assessed. 
Reversibility with a bronchodilator is also a criterion for 
differential diagnosis between asthma and COPD. Even 
when inflammation and not bronchodilator response 
distinguishes between the two disorders, the degree of 
bronchial responsiveness is a commonly used criterion to 
separate asthma and COPD in clinical practice and 
inclusion in clinical trials. In this study, none of the indices 
resulted in a good differentiation between the two disorders. 
This is in agreement with previous studies, indicating that 
up to 23% of asthmatics showed a non-responsive 
spirometry (5). The most powerful indices found to 
separate asthma and COPD in this population were dabs 
and A%pred, which showed the highest likelihood ratios 
(dabs, 2.23 and A%pred, 2.03) and thus the best combina- 
tion of sensitivity, and specificity, compared to A%init 
(likelihood ratio 1.28). When analysing the discriminative 
value of each index solely by considering differences in 
group means, all indices reached a statistically significant 
difference if only patients with reduced FEVi were 
considered. However, in a more complete analysis, the 
sensitivity, the specificity and likelihood ratios were not 
substantially modified by excluding patients with near- 
normal baseline FEVi . Published studies disagree consider- 
ably on this point. While Nicklaus (6), assessing only 
A%init, showed a strong discriminative power for bronch- 
odilator response, Brand et al. (8) found this method to be a 
poor diagnostic criterion. This disagreement may again be 
explained by different population compositions and meth- 
ods of analysis. Discriminative power may be evaluated 
using group mean differences (17) or by including sensitivity 
and specificity calculations (8,24) and, even when the same 
method is used, different inclusion criteria and doses of 
bronchodilator may influence the final results. It is 
remarkable that, in the present study, even the best indices 
were not sensitive for asthma diagnosis. It is important to 
remember that clinical background is critically significant in 
defining predictive values and thus to delimit the increase in 
diagnostic power using each index. With a low pre-test 
probability of asthma (30%), even the best indices in this 
study showed low predictive values for a positive test, 
however these reached clinical relevance with higher pre- 
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test probabilities. This emphasizes that, in a clinical setting, 
the occurrence of a negative test does not exclude the 
presence of asthma, even when a better diagnosis may be 
obtained by dabs or A%pred. 
We conclude that: 1. in clinical practice A%init is a poor 
diagnostic tool to differentiate asthma from COPD; 2. in 
patients with a previously known diagnosis, A%init over- 
estimates the response to bronchodilator in subjects with 
very low baseline FEVi; and 3. in clinical trials studying 
reversibility, the chosen index should be assessed to exclude 
dependence on the initial FEVi. The expression which 
correlates best with clinical improvement after long-term 
treatment has not yet been defined, therefore the inclusion 
of different indices for expressing bronchodilator response 
in clinical trials studying the effects of long-term inhala- 
tional therapy would be extremely useful. 
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